Free Trial

Zentalis Pharmaceuticals (ZNTL) Competitors

Zentalis Pharmaceuticals logo
$1.49 -0.07 (-4.49%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$1.52 +0.02 (+1.68%)
As of 10/17/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZNTL vs. INBX, ATXS, CYRX, SLDB, ALMS, DRUG, LXEO, RAPT, AUTL, and CGEM

Should you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include Inhibrx Biosciences (INBX), Astria Therapeutics (ATXS), CryoPort (CYRX), Solid Biosciences (SLDB), Alumis (ALMS), Bright Minds Biosciences (DRUG), Lexeo Therapeutics (LXEO), Rapt Therapeutics (RAPT), Autolus Therapeutics (AUTL), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry.

Zentalis Pharmaceuticals vs. Its Competitors

Inhibrx Biosciences (NASDAQ:INBX) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

Zentalis Pharmaceuticals' return on equity of -51.62% beat Inhibrx Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Inhibrx BiosciencesN/A -137.83% -76.31%
Zentalis Pharmaceuticals N/A -51.62%-40.28%

Inhibrx Biosciences has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inhibrx Biosciences$200K2,696.90$1.69B-$10.58-3.52
Zentalis Pharmaceuticals$67.43M1.59-$165.84M-$2.26-0.66

In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 1 mentions for Zentalis Pharmaceuticals and 0 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.00 equaled Zentalis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Inhibrx Biosciences Neutral
Zentalis Pharmaceuticals Neutral

82.5% of Inhibrx Biosciences shares are held by institutional investors. 17.1% of Inhibrx Biosciences shares are held by company insiders. Comparatively, 1.9% of Zentalis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Inhibrx Biosciences has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500.

Zentalis Pharmaceuticals has a consensus price target of $5.84, suggesting a potential upside of 291.95%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than Inhibrx Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inhibrx Biosciences
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Zentalis Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.33

Summary

Zentalis Pharmaceuticals beats Inhibrx Biosciences on 11 of the 15 factors compared between the two stocks.

Get Zentalis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZNTL vs. The Competition

MetricZentalis PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$107.48M$3.44B$6.21B$10.54B
Dividend YieldN/A2.28%5.70%4.81%
P/E Ratio-0.6623.1685.7027.13
Price / Sales1.59506.66617.13193.73
Price / CashN/A46.9237.1060.81
Price / Book0.3210.4112.236.52
Net Income-$165.84M-$52.77M$3.33B$276.93M
7 Day Performance-11.31%2.31%1.17%1.93%
1 Month Performance-1.97%12.59%6.85%2.19%
1 Year Performance-52.55%11.18%58.93%34.62%

Zentalis Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZNTL
Zentalis Pharmaceuticals
1.6854 of 5 stars
$1.49
-4.5%
$5.84
+291.9%
-52.5%$107.48M$67.43M-0.66160
INBX
Inhibrx Biosciences
1.6503 of 5 stars
$34.38
+5.9%
N/A+132.8%$470.27M$200K-3.25166
ATXS
Astria Therapeutics
1.9236 of 5 stars
$8.47
+1.9%
$29.50
+248.3%
+4.5%$468.97MN/A-4.2130Trending News
Analyst Downgrade
CYRX
CryoPort
3.2053 of 5 stars
$9.40
+1.1%
$12.56
+33.6%
+34.0%$465.62M$228.38M7.071,186News Coverage
SLDB
Solid Biosciences
3.0107 of 5 stars
$6.01
+0.8%
$15.00
+149.6%
-10.9%$464.10M$8.09M-2.15100News Coverage
Analyst Downgrade
ALMS
Alumis
3.4371 of 5 stars
$4.61
+3.8%
$20.17
+337.5%
-62.7%$462.05MN/A0.00N/APositive News
Gap Down
DRUG
Bright Minds Biosciences
3.2181 of 5 stars
$64.97
+2.7%
$81.00
+24.7%
+33.7%$445.81MN/A-69.86N/APositive News
LXEO
Lexeo Therapeutics
3.0631 of 5 stars
$8.20
-0.5%
$17.00
+107.3%
-13.8%$444.97M$650K-2.5258Trending News
Analyst Forecast
Insider Trade
RAPT
Rapt Therapeutics
3.1655 of 5 stars
$26.35
-1.6%
$24.78
-6.0%
+104.9%$443.05M$1.53M-1.8680Analyst Revision
Gap Up
AUTL
Autolus Therapeutics
3.5552 of 5 stars
$1.65
-0.6%
$9.12
+452.7%
-66.3%$441.80M$10.12M-1.96330
CGEM
Cullinan Therapeutics
3.5599 of 5 stars
$7.83
+5.8%
$26.00
+232.1%
-53.1%$437.15MN/A-2.4230News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:ZNTL) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners